The role of comprehensive gene profiling tests in pancreatic cancer

Abstract

The comprehensive genomic profiling (CGP) test using a multiplex gene panel has been reimbursed by the National Health Insurance System since June 2019. A liquid biopsy using blood specimens has been added as an option for CGP since August 2021. The results of CGP must be annotated by a molecular tumor board called an "expert panel", which includes multidisciplinary specialists. Currently, the indications for CGP are limited to patients with advanced solid tumors who have completed or are expected to complete standard treatment. Since it takes almost 6 to 8 weeks from the time of application for the CGP test until the results are returned to the patient, it is necessary to pay careful attention to this detail when applying for a CGP test for a patient with pancreatic cancer which often progresses in a short time and has a poor prognosis. Although the percentage of patients who receive treatment based on the results of CGP test is less than 10%, progress in precision medicine using CGP will increase the proportion of patients who receive treatment based on CGP and improve the prognosis of patients with pancreatic cancer.